Key Insights

Highlights

Treatment Research

1 treatments under study, led by Pd1pdl1ctla4 Inhibitors

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 1 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

1Total
Phase 2/3 (1)

Trial Status

Recruiting1

Clinical Trials (1)

Showing 1 of 1 trials
NCT03952065Phase 2/3RecruitingPrimary

IT or IA Infusion of PD1/PDL1/CTLA4 Inhibitors Versus IV for Immunotherapy of Head/Neck Cancers (HNC)

Showing all 1 trials

Research Network

Common Treatments

  • Pd1pdl1ctla4 Inhibitors1

Active Sponsors

  • Second Affiliated Hospital of Guangzhou Medical University1

Top Investigators

Activity Timeline